Aug. 20 at 11:47 AM
$SANA barring an acquisition, partnership, or licensing (all of which are possible, especially with recent published data), the major news for Sana is in for the year. Headline: Data stellar (hypoimmune is reproducible and works in 12 humans), dilution was not that bad, runway extended by minimum 1 year (possibly enough to start sc451 transplant). As I called earlier, the selloff was completely overblown. In hindsight, it will probably end up looking like an insignificant pullback. Nothing to do but dollar cost average and/or hold now.
Big money scooped up shares cheap and closed some of their shorts. just eat some popcorn and watch them bid it up.
